Two UK speciality pharmaceutical companies, Sinclair Pharma Plc and IS Pharma Plc, have reached agreement on the terms of an all-share merger that will create a new UK-based speciality pharma business with product distribution throughout Europe.
The nonprofit drug discovery affiliate of the Cystic Fibrosis Foundation is expanding a collaboration with Vertex Pharmaceuticals Inc to develop new medicines called ‘correctors’ that aim to treat the underlying cause of cystic fibrosis.
Privately-held Astex Therapeutics Ltd of the UK has agreed to be acquired by the California-based oncology drug developer SuperGen Inc to create a new publicly-listed entity with a combined clinical pipeline of eight products.
The US Food and Drug Administration has approved gabapentin enacarbil for the treatment of restless legs syndrome in adults. The drug was developed by XenoPort Inc of the US. GlaxoSmithKline Plc is a commercial partner.
The US Food and Drug Administration has announced the approval of vandetanib from AstraZeneca Plc for the treatment of patients with late-stage medullary thyroid cancer who are ineligible for surgery. The decision was announced on 6 April.
Reliance GeneMedix Plc, which is part of the Reliance Life Sciences Group in India, has withdrawn a marketing authorisation application for erythropoietin from the European Medicines Agency. It cited its inability to supply additional data.
Merck & Co has reached agreement to acquire the US speciality pharmaceutical company, Inspire Pharmaceuticals Inc, for $430 million. The transaction has been unanimously approved by the boards of directors of both companies.
It is something of a truism to say that money follows success. It is less easy to say why some companies are more successful than others, and how their successes can be repeated.
Evolva Holding SA of Switzerland, which specialises in synthetic biology, has announced plans to acquire the US venture-capital backed Abunda Nutrition Inc in an all-share transaction valued at approximately CHF 40.5 million (€31.3 million).
The AstraZeneca Plc unit, MedImmune, has entered into a three-year collaboration with the technology transfer arm of France’s National Institute of Health and Medical Research (Inserm) to research disease and potential drug candidates.